EPHA1 and neoplasm: Our findings underscore the complexity and versatility of the Eph–Ephrin system, prompting a re-evaluation of traditional agonist or antagonist design strategies and opening new avenues for innovative therapeutic interventions aimed at modulating tumor progression.